Acadian Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Acadian Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$186K	Sell	20,109 -10,022	-33%	-$87.2K	﹤0.01%	1610
2025 Q4	$225K	Sell	30,131 -24,970	-45%	-$253K	﹤0.01%	1497
2025 Q3	$478K	Sell	55,101 -275,490	-83%	-$1.65M	﹤0.01%	1235
2025 Q2	$1.23M	Sell	330,591 -70,015	-17%	-$246K	﹤0.01%	942
2025 Q1	$1.29M	Buy	400,606 +367,317	+1,103%	+$1.73M	﹤0.01%	869
2024 Q4	$185K	Buy	+33,289	New	+$261K	﹤0.01%	1269
2022 Q4	–	Sell	-56,592	Closed	-$454K	–	1825
2022 Q3	$454K	Sell	56,592 -38,367	-40%	-$347K	﹤0.01%	1015
2022 Q2	$663K	Buy	+94,959	New	+$923K	﹤0.01%	904

Other funds holding FDMT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Acadian Asset Management's FDMT Position: Q1 2026 in Review

Acadian Asset Management reduced its 4D Molecular Therapeutics (FDMT) stake by 33% in Q1 2026, selling an estimated $87.2K and leaving 20,109 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #1610.

Acadian Asset Management first reported a position in FDMT in Q2 2022 and has held it in 8 quarters since. The position peaked at $1.29M in Q1 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

Acadian Asset Management held 20,109 shares of 4D Molecular Therapeutics worth $186K as of Q1 2026.
Acadian Asset Management sold 10,022 4D Molecular Therapeutics shares in Q1 2026, an estimated $87.2K.
4D Molecular Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1610 holding.
Acadian Asset Management first reported a position in 4D Molecular Therapeutics in Q2 2022 and has held it in 8 quarters since.
Acadian Asset Management's 4D Molecular Therapeutics position peaked at $1.29M in Q1 2025.
152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.